Number of the records: 1
Inflammation as target in cancer therapy.
- 1.
SYSNO ASEP 0483220 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Inflammation as target in cancer therapy. Author(s) Marelli, G. (IT)
Sica, A. (IT)
Vannucci, Luca (MBU-M) RID, ORCID
Allavena, P. (IT)Source Title Current Opinion in Pharmacology. - : Elsevier - ISSN 1471-4892
Roč. 35, August 2017 (2017), s. 57-65Number of pages 9 s. Language eng - English Country GB - United Kingdom Keywords cancer therapy ; cancer-promoting inflammation ; Tumour-Associated Macrophages Subject RIV EE - Microbiology, Virology OECD category Microbiology Institutional support MBU-M - RVO:61388971 UT WOS 000419664900009 DOI 10.1016/j.coph.2017.05.007 Annotation Cells of the innate immunity infiltrating tumour tissues promote, rather than halt, cancer cell proliferation and distant spreading. Tumour-Associated Macrophages (TAMs) are abundantly present in the tumour milieu and here trigger and perpetrate a state of chronic inflammation which ultimately supports disease development and contributes to an immune-suppressive environment. Therapeutic strategies to limit inflammatory cells and their products have been successful in pre-clinical tumour models. Early clinical trials with specific cytokine and chemokine inhibitors, or with strategies designed to target TAMs, are on their way in different solid malignancies. Partial clinical responses and stabilization of diseases were observed in some patients, in the absence of significant toxicity. These encouraging results open new perspectives of combination treatments aimed at reducing cancer-promoting inflammation to maximize the anti-tumour efficacy. Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2018
Number of the records: 1